Growth inhibitors in the treatment of malignant neoplasms

In Vivo

Volumn 14, Issue 1, 2000, Pages 287-296

  Kaiser, Hans E ^a,b   Krenn, Michaela ^c   Bodey Jr , Bela ^d   Bodey, Bela ^d,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b International Institute of Anticancer Research   (Greece)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE   (United States)

Author keywords

Angiogenesis or neovascularization; Apoptosis or programmed cell death (PCD); Cell cycle; Cellular immunophenotype (CIP); Cytokines; Feedback inhibitors; Fourth modality therapies; Growth factors; Hormones; Monoclonal antibody(MoAB); Multidrug resistance (MDR); Neoplastic transformation

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZALDEHYDE; CHALONE; CYCLIC AMP DERIVATIVE; CYTOKINE; DILTIAZEM; GLYCOPROTEIN P; GROWTH FACTOR; GROWTH INHIBITOR; INTERFERON; NIFEDIPINE; PROLINE DERIVATIVE; PROSTAGLANDIN DERIVATIVE; PROTEINASE INHIBITOR; RETINOID; STEROID HORMONE; VERAPAMIL;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CARCINOGENESIS; CELL CYCLE; CELL TRANSFORMATION; DRUG MECHANISM; GENE INACTIVATION; GROWTH INHIBITION; HUMAN; IMMUNOPHENOTYPING; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE;

EID: 0034075537     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. McCarty MF: Cytostatic and reverse-transforming therapies of cancer - a brief review and future prospects. Med Hypotheses 8: 589-612, 1982.
2. Marshall E and Lord BI: Feedback inhibitors in normal and tumor tissues. Int Rev Cytol 167: 185-261, 1996.
3. Byrne HM, Chaplin MA: Growth of necrotic tumors in the presence and absence of inhibitors. Math Biosci 135: 187-216, 1996.
4. Tisch M, Heimlich F, Daniel V, Opelz G, Maier H: Cellular immune defect caused by postsurgical radiation therapy in patients with head and neck cancer. Otolaryngol Head Neck Surg 119: 412-417, 1998.
5. Fynan TM, Reiss M: Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 4: 493-540, 1993.
6. Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB: Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 141: 353-61, 1989.
7. Krasagakis K, Kruger-Krasagakes S, Fimmel S, Eberle J, Tholke D, von der Ohe M, Mansmann U, Orfanos CE: Desensitization of melanoma cells to autocrine TGF-beta isoforms. J Cell Physiol 178: 179-187, 1999.
8. Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G: Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 36: 409-416, 1993.
9. Christensen ME: The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan Med Bull 45: 121-134, 1998.
10. Ciardiello F, Tortora G: Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin Cancer Res 4: 821-828, 1998.
11. Leenders WP: Targetting VEGF in anti-angiogenic and anti-tumour therapy: where are we now? Int J Exp Pathol 79: 339-346, 1998.
12. Akhurst RJ, Balmain A: Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol 187: 82-90, 1999.
13. Ananth S, Knebelmann B, Gruning W, Dhanabal M, Walz G, Stillman IE, Sukhatme VP: Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59: 2210-2216, 1999.
14. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT, Cho JS, Ilio KY, Cronauer MV, Janulis L, Sensibar JA: Transforming growth factor-beta in benign and malignant prostate. Prostate 39: 285-290, 1999.
15. Yu H, Berkel H: Insulin-like growth factors and cancer. J La State Med Soc 151: 218-223, 1999.
16. Zeinoun Z, Teugels E, De Bleser PJ, Neyns B, Geerts A, De Greve J: Insufficient TGF-beta 1 production inactivates the autocrine growth suppressive circuit in human ovarian cancer cell lines.Anticancer Res 19: 413-420, 1999.
17. Roberts AB, Frolik CA, Anzano MA, Sporn MB: Transforming growth factors from neoplastic and nonneoplastic tissues. Fed Proc 22: 2621-2626, 1983.
18. Frolik CA, Wakefield LM, Smith DM, Sporn MB: Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. J Biol Chem 259: 10995-11000, 1984.
19. Tucker RF, Branum EL, Shipley GD, Ryan RJ, Moses HL: Specific binding to cultured cells of 1251-labeled type beta transforming growth factor from human platelets. Proc Natl Acad Sci USA 81: 6757-6761, 1984.
20. Massague J: Type beta transforming growth factor from feline sarcoma virus-transformed cells. Isolation and biological properties. J Biol Chem 259: 9756-9761, 1984.
21. Segarini PR: TGF-beta receptors. Clinical applications of TGF-beta. Wiley, Chichester (CIBA Foundation Symposium # 157), 1991; pp. 29-50.
22. Massague J, Andres J, Attisano L, Cheifetz S, Lopez-Casillas F, Ohtsuki M, Wrana JL: TGF-beta receptors. Mol Repr Dev 32: 99-104, 1992.
23. Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zentella A: Transforming growth factor-beta. Cancer Surv 12: 81-103, 1992.
24. Cheifetz S, Weatherbee JA, Tsang ML-S, Anderson JK, Mole JE, Lucas R, Massague J: The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48: 409-415, 1987.
25. Massague J, Like B: Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J Biol Chem 260: 2636-2645, 1985.
26. Wrana JL, Carcamo J, Attisano L, Cheifetz S, Zentella A, Lopez-Casillas F, Massague J: The type II TGF-beta receptor signals diverse responses in cooperation with the type I receptor. Cold Spring Harb Symp Quant Biol 57: 81-86, 1992.
27. Bodey B, Grωger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17: 493-498, 1997.
28. Laiho M, Weis FMB, Boyd FT, Ignotz RA, Massague J: Responsiveness of transforming growth factor beta (TGF-beta) restored by genetic complementation between cells defective in TGF-beta receptors I and II. J Biol Chem 266: 9108-9112, 1992.
29. Miyazono K: TGF-beta receptors and signal transduction. Int J Hematol 65: 97-104, 1997.
30. Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 68: 775-785, 1992.
31. Bodey B, Bodey B Jr, Hall FL: Expression of Transforming Growth Factor-beta type II receptors in the cells of the human thymic microenvironment during ontogenesis. In: Molecular Biology of Hematopoiesis. Volume V. (Abraham NG, Asano S, Brittinger G, Maestroni GJM, Shadduck R, eds) New York, Plenum Press, 1996, Chapter 78, pp. 645-658.
32. Krasagakis K, Garbe C, Schrier PI, Orfanos CE: Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res 14: 2565-2571, 1994.
33. Andalib AR, Lawry J, Ali SA, Murray AK, Sisley K, Silcocks P, Herlyn M, Rees RC: Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumour tissues. Melanoma Res 7: 32-42, 1997.
34. Ma D, Niederkorn JY: Transforming growth factor-beta downregulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 86: 263-269, 1995.
35. Vanky F, Nagy N, Hising C, Sjovall K, Larson B, Klein E: Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 43: 317-323, 1997.
36. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, Giannotti B: In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7: 313-321, 1997.
37. Teti A, De Giorgi A, Spinella MT, Migliaccio S, Canipari R, Onetti Muda A, Faraggiana T: Transforming growth factor-beta enhances adhesion of melanoma cells to the endothelium in vitro. Int J Cancer 72: 1013-1020, 1997.
38. Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE: Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 148: 1887-1894, 1996.
39. Reed JA, McNutt NS, Prieto VG, Albino AP: Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 145: 97-104, 1994.
40. Perletti GP, Marras E, Concari P, Piccinini F, Tashjian AH Jr.: PKCdelta acts as a growth and tumor suppressor in rat colonic epithelial cells. Oncogene 18: 1251-1256, 1999.
41. Negrier S: Cytokines and cancer: update in 1998. Bull Cancer 86: 37-39, 1999.
42. Beckwith M, Longo DL, O'Connell CD, Moratz CM, Urba WJ: Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst 1990 82: 501-509, 1990.
43. Yan DH, Wen Y, Spohn B, Choubey D, Gutterman JU, Hung MC: Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202, Oncogene 18: 807-811, 1999.
44. Reiter Z, Ozes ON, Blatt LM, Sturzl M, Taylor MW: A possible role for interferon-alpha and activated natural killer cells in remission of AIDS-related Kaposi's sarcoma: in vitro studies. J Acquir Immune Defic Syndr 5: 469-476, 1992.
45. Campbell MJ, Dawson M, Koeffler HP: Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Br J Cancer 77: 739-744, 1998.
46. Lukas J, Sorensen CS, Lukas C, Santoni-Rugiu E, Bartek J: p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis. Oncogene 18: 3930-3935, 1999.
47. Seewaldt VL, Kim JH, Caldwell LE, Johnson BS, Swisshelm K, Collins SJ All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ 8: 631-641, 1997.
48. Lichti U, Yuspa SH: Inhibition of epidermal terminal differentiation and tumour promotion by retinoids. Ciba Found Symp 113: 77-89, 1985.
49. Alcain FJ, Buron MI: Ascorbate on cell growth and differentiation. J Bioenerg Biomembr 26: 393-398, 1994.
50. Hilakivi-Clarke L, Cho E, Clarke R: Maternal genistein exposure mimics the effects of estrogen on mammary gland development in female mouse offspring. Oncol Rep 5: 609-616, 1998.
51. Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z: Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52: 6200-6208, 1992.
52. Constantinou AI, Krygier AE, Mehta RR: Genistein induces maturation of cultured human breast cancer cells and prevents tumor growth in nude mice. Am J Clin Nutr 68: 1426S-1430S, 1998.
53. Wark G, Heyworth CM, Spooncer E, Czaplewski L, Francis JM, Dexter TM, Whetton AD: Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha. Oncogene 16: 1319-1324, 1998.
54. Katdare M, Osborne MP, Telang NT: Inhibition of aberrant proliferation and induction of apoptosis in pre-neoplastic human mammary epithelial cells by natural phytochemicals. Oncol Rep 5: 311-315, 1998.
55. Estrov Z, Black RA, Sleath PR, Harris D, Van O, LaPushin R, Estey EH, Talpaz M: Effect of interleukin-1 beta converting enzyme inhibitor on acute myclogenous leukemia progenitor proliferation. Blood 86: 4594-4602, 1995.
56. Lovett D, Kozan B, Hadam M, Resch K, Gemsa D: Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. J Immunol 136: 340-347, 1986.
57. Forni G, Musso T, Jemma C, Boraschi D, Tagliabue A, Giovarelli M: Lymphokine-activated tumor inhibition in mice. Ability of a nonapepticle of the human IL-1 beta to recruit anti-tumor reactivity in recipient mice. J Immunol 142: 712-718, 1989.
58. Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM: P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 5: 1452-1460, 1987.
59. Weide R, Dowding C, Paulsen W, Goldman JM: The role of MDR-1/p-170 mechanism in the development of multidrug resistance in chronic mycloid leukemia (CML). (Abstract), Exper Hematol 18: 645, 1990.
60. Simon SM, Scindler M: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91: 3497-3504, 1994.
61. Gottesman MM, Pastan I: The multidrug transport, a double-edged sword. J Biol Chem 263: 12163-12166, 1988.
62. Pastan I, Gottesman MM: Multiple-drug resistance in human cancer. New Engl J Med 316: 1388-1393, 1987.
63. Endicott JA, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
64. Wunder JS, Bell RS, Wold L, Andrulis L: Expression of the Multidrug Resistance Gene in osteosarcoma: A pilot study. J Orthopaedic Res 11: 396-403, 1993.
65. Kane SE, Pastan I, Gottesman MM: Genetic basis of multidrug resistance of tumor cells. J Bioenerg Biomembr 22: 593-618, 1990.
66. Willingham MC, Richert ND, Cornwell MM, Tsuruo T, Hamada H, Gottesman MM, Pastan IH: Immunocytochemical localization of p170 at the plasma membranes of multidrug-resistant human cells. J Histochem Cytochem 35: 1451-1456, 1987.
67. Hamada H, Tsuruo T: Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785-7789, 1986.
68. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein p170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37: 159-164, 1989.
69. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S" Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res 48: 1926-1929, 1988.
70. Akiyama S-I, Fojo A, Hanover JA, Pastan I, Gottesman MM: Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol Genet 11: 117-126, 1985.
71. Roninson IB, Chin JE, Choi KG, Honsman DE, Fojo A, Shen DW, Gottesman MM, Pastan I: Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83: 4538-4542, 1986.
72. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM: Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 232: 643-645, 1986.
73. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389, 1986.
74. Fojo AT, Akiyama S-I, Gottesman MM, Pastan I: Reduced drug accumulation in multiple drug-resistant human KB carcinoma cell lines. Cancer Res 45: 3002-3008, 1985.
75. Horio M, Gottesman MM, Pastan IH: ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 85: 3580-3584, 1988.
76. Kessel D, Bosmann HB: On the characteristics of astinomycin D resistance in L5178Y cells. Cancer Res 30: 2695-2701, 1970.
77. Riehm H, Biedler JL: Cellular resistance to daenomycin in Chinese hamster cells in vitro. Cancer Res 31: 409-412, 1971.
78. Ling V, Gerlach J, Kartner N: Multidrug resistance. Breast Cancer Res Treat 4: 89-94, 1984.
79. Ling V, Kartner N, Sudo T, Simonovitch L, Riordan JR: Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 67: 869-874, 1983.
80. Sirotnak FM, Yang CH, Mines LS, Oribe E, Biedler JL: Markedly altered membrane transport and intracellular binding of vincristine in multidrug-resistant Chinese hamster cells selected for resistance to vinca alkaloids. J Cell Physiol 126: 266-274, 1986.
81. Siegfried JA, Kennedy KA, Sartorelli AC, Tritton TR: The role of membranes in the mechanism of action of the antineoplastic drug adriamycin. Spin-labeling studies with chronically hypoxic and drug-resistant tumor cells. J Biol Chem 258: 339-343, 1983.
82. Ramu A, Glaubiger D, Magrath IT, Joshi A: Plasma membrane lipid structural order in doxorubicin-sensitive and -resistant P388 cells. Cancer Res 43: 5533-5537, 1983.
83. Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surg 5: 25-46, 1986.
84. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162, 1976.
85. Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, Alberts DS: Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 48: 6365-6370, 1988.
86. Safa AR: Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 85: 7187-7191, 1988.
87. Beck WT, Cirtain MC, Lefko JL: Energy-dependent reduced drug binding as a mechanism of vinca alkaloid resistance in human leukemic lymphoblasts. Mol Pharmacol 24: 485-492, 1983.
88. Safa AR, Glover CJ, Meyers MB, Biedler JL, Felsted RL: Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J Biol Chem 261: 6137-6140, 1986.
89. Cornwell MM, Safa AR, Felsted RL, Gottesman MM, Pastan IH: Membrane vesicles from multidrug-resistant cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci USA 83: 3847-3850, 1986.
90. Hamada H, Tsuruo T: Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res 48: 4926-4932, 1988.
91. Michieli M, Damiani D, Geromin A, Michelutti A, Famin R, Raspadori D, Russo D, Visani G, Dinota A, Pileri S, Tsuruo T, Grandi M, Baccarani M, Tura S, et al: Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 48: 87-92, 1992.
92. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsurno T, Troncy T, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79: 473-476, 1992.
93. van der Bliek AM, Borst P: Multidrug resistance. Adv Cancer Res 47: 489-494, 1989.
94. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832-10836, 1992.
95. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149-153, 1995.
96. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
97. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
98. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
99. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res 18: 1485-1500, 1998.
100. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res 18: 2701-2710, 1998.
101. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Over-expression of endoglin (CD105): A marker of breast carcinoma-induced neovascularization. Anticancer Res 18: 3621-3628, 1998.
102. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13: 765-782, 1995.
103. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275: 150-154, 1996.
104. Folkman J: New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A: 2534-2539, 1996.
105. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834, 1997.
106. D'Amato RJ, Loughman MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
107. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660, 1994.
108. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL: AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34: 869-875, 1994.
109. Bosse DC, Parker JT, Vogler WR, Ades EW: Selective inhibition of adhesion molecule expression by edelfosine (ET-18-OCH3) on human umbilical vein or microvascular endothelium. Pathobiology 63: 109-114, 1995.
110. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 87: 581-586, 1995.
111. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S: Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 77: 1736-1740, 1996.
112. Maier JA, Delia D, Thorpe PE, Gasparini G: In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 8: 238-244, 1997.
113. Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS: Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57: 5277-5280, 1997.
114. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
115. Klauber N, Parangi S, Flynn E, Hamel, E, D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86, 1997.
116. Sim BKL, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA: A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57: 1329-1334, 1997.
117. Boehm T, Folkman J, Browder TT, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
118. Lindner DJ, Borden BC: Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer 71: 456-461, 1997.
119. Meir EG van, Polverini PI, Chazin VR, Su Huang HJ, Tribolet N de, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nature Genet 8: 171-176, 1994.
120. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
121. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS: Oncogenes as inducers of tumor angiogenesis.Cancer Metastasis Rev 14: 263-277, 1995.
122. Plate KH: Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metast Rev 15: 237-240, 1996.
123. Wojtowicz-Praga S, Verma UN, Wakefield L, Esteban JM, Hartmann D, Mazumder A: Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Emphasis Tumor Immunol 19: 169-175, 1996.
124. Normanno N, De Luca A, Salomon DS, Ciardiello F: Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma. Cancer Detect Prev 22: 62-67, 1998.
125. Bodey B, Siegel SE, Kaiser HE: Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Anticancer Res 16: 661-674, 1996.
126. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Genetically engineered mouse antibodies for anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Current Pharmaceutical Design, (in print), 1999.